225 related articles for article (PubMed ID: 36428682)
1. Antitumor Activities of Interleukin-12 in Melanoma.
Gao W; Pan J; Pan J
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428682
[TBL] [Abstract][Full Text] [Related]
2. Cytokines in the Treatment of Melanoma.
Bentebibel SE; Diab A
Curr Oncol Rep; 2021 May; 23(7):83. PubMed ID: 34003395
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
Roberts JD; Niedzwiecki D; Carson WE; Chapman PB; Gajewski TF; Ernstoff MS; Hodi FS; Shea C; Leong SP; Johnson J; Zhang D; Houghton A; Haluska FG;
J Immunother; 2006; 29(1):95-101. PubMed ID: 16365605
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activities of interleukin-27 on melanoma.
Nagai H; Oniki S; Fujiwara S; Xu M; Mizoguchi I; Yoshimoto T; Nishigori C
Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):41-6. PubMed ID: 19845503
[TBL] [Abstract][Full Text] [Related]
5. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
7. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
Marabondo S; Kaufman HL
Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820
[TBL] [Abstract][Full Text] [Related]
8. Cytokine-based therapy and biochemotherapy for advanced melanoma.
Atkins MB
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
[TBL] [Abstract][Full Text] [Related]
9. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses.
Müller J; Feige K; Wunderlin P; Hödl A; Meli ML; Seltenhammer M; Grest P; Nicolson L; Schelling C; Heinzerling LM
J Immunother; 2011 Jan; 34(1):58-64. PubMed ID: 21150713
[TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
11. Interleukins in the treatment of melanoma.
Xu X; Dai W; Li C
Chin Med J (Engl); 2022 Jan; 135(4):393-399. PubMed ID: 34985017
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
14. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
15. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial.
Charles J; Chaperot L; Hannani D; Bruder Costa J; Templier I; Trabelsi S; Gil H; Moisan A; Persoons V; Hegelhofer H; Schir E; Quesada JL; Mendoza C; Aspord C; Manches O; Coulie PG; Khammari A; Dreno B; Leccia MT; Plumas J
Oncoimmunology; 2020; 9(1):1738812. PubMed ID: 32313721
[TBL] [Abstract][Full Text] [Related]
16. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
18. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
20. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]